10-Q: SANUWAVE Health Reports Strong Revenue Growth in Q3 2024 Despite Ongoing Financial Challenges

Sentiment:

Quarterly Report 7 November 2024 5:08 PM

SANUWAVE Health experienced a significant 89% increase in revenue for the third quarter of 2024 compared to the same period last year, while still navigating financial difficulties.

Capital raiseThe company plans to obtain additional capital in 2024 through various means.The company could obtain additional capital through the conversion of outstanding warrants, issuance of common or preferred stock, securities convertible into common stock, or secured or unsecured debt.On October 16, 2024, the company entered into a securities purchase agreement for a private placement of approximately 1.3 million shares of common stock at a purchase price of $8.25 per share, raising approximately $10.3 million.

Worse than expectedThe company's senior secured debt is in default, indicating a significant financial challenge.The company has a working capital deficit, raising concerns about its ability to meet its short-term obligations.There is substantial doubt about the company's ability to continue as a going concern, which is a critical negative indicator.

Summary

SANUWAVE Health reported an 89% increase in revenue for the three months ended September 30, 2024, reaching $9.4 million, compared to $5.0 million in the same period of 2023.
The company's revenue for the nine months ended September 30, 2024, totaled $22.3 million, a 66% increase from $13.4 million in the same period of 2023.
The net loss for the three months ended September 30, 2024, was $20.7 million, an improvement from the $23.7 million loss in the same period of 2023.
The net loss for the nine months ended September 30, 2024, was $18.6 million, a significant decrease from the $44.0 million loss in the same period of 2023.
The company's operating income for the three months ended September 30, 2024, was $2.0 million, a $2.5 million improvement compared to the same period in 2023.
Operating income for the nine months ended September 30, 2024, was $2.9 million, a $4.5 million improvement compared to the same period in 2023.
The company is in default on its senior secured debt and has a working capital deficit, raising concerns about its ability to continue as a going concern.
A one-for-three hundred seventy-five (1:375) reverse stock split was effected on October 18, 2024.

Sentiment

Score: 4

Explanation: While the company shows strong revenue growth and improved operating income, the significant net losses, debt default, going concern issues, and material weaknesses in internal controls create a negative outlook. The recent capital raise and debt restructuring provide some hope, but the overall financial situation remains precarious.

Positives

The company experienced significant revenue growth in both the three and nine month periods ending September 30, 2024.
The company's net loss decreased significantly in both the three and nine month periods ending September 30, 2024.
Operating income improved substantially in both the three and nine month periods ending September 30, 2024.
The company secured a $2.5 million payment from a patent license agreement.
The company recognized a $5.3 million gain on debt extinguishment.

Negatives

The company is in default on its senior secured debt.
The company has a significant working capital deficit.
There is substantial doubt about the company's ability to continue as a going concern.
The company's warrant liability increased significantly to $35.5 million as of September 30, 2024, from $14.4 million at the end of 2023.
The company's accrued interest liability remains high at $643,000, with an additional $952,000 owed to related parties.

Risks

The company's ability to continue as a going concern is dependent on raising additional capital.
The company may not be able to raise additional capital on favorable terms, which could lead to significant dilution for existing stockholders.
The company's senior secured debt is in default, which could lead to further financial difficulties.
The company has identified material weaknesses in its internal controls over financial reporting.
The company relies on single suppliers for most of its product component materials, which could disrupt production if a supplier is lost.

Future Outlook

The company expects to devote substantial resources for the commercialization of UltraMIST and PACE systems, which will require additional capital resources. Management plans to obtain additional capital in 2024 through various means, including the conversion of outstanding warrants, issuance of stock, or secured or unsecured debt.

Management Comments

Management is fully committed to addressing the material weaknesses in our internal controls.
Management plans to remediate and implement controls for high-risk processes throughout 2024.
Management believes that providing non-GAAP financial information to investors allows them to see the company's results through the eyes of management.

Industry Context

The company operates in the medical device industry, focusing on non-invasive and biological response activating medical systems. The company's revenue growth suggests increasing market acceptance of its UltraMIST system, but the financial challenges highlight the competitive and capital-intensive nature of the industry.

Comparison to Industry Standards

The company's revenue growth of 89% in Q3 2024 is significant, but it is difficult to compare directly to industry standards without knowing the specific market segment and competitive landscape.
The company's gross margin of 76% in Q3 2024 is relatively high, but it is important to consider the company's specific product mix and cost structure.
The company's net loss of $20.7 million in Q3 2024 is substantial, and it is important to compare this to the performance of similar companies in the medical device industry.
The company's reliance on debt financing and the default on its senior secured debt are concerning and may indicate a higher risk profile compared to industry peers with stronger balance sheets.
The company's material weaknesses in internal controls are a significant concern and need to be addressed to ensure the reliability of financial reporting.

Legal Proceedings

The company settled a dispute with Celularity in June 2024 for $2.2 million, resulting in a gain on extinguishment of debt of $5.3 million.

Related Party Transactions

The company entered into a $0.5 million promissory note with a related party in June 2024.

Stakeholder Impact

Shareholders face significant risk due to the company's financial instability and potential dilution from future capital raises.
Employees may be impacted by potential cost-cutting measures or restructuring if the company's financial situation does not improve.
Customers may be concerned about the company's ability to continue providing products and services.
Suppliers may face increased risk of non-payment due to the company's financial difficulties.
Creditors face increased risk of default due to the company's debt burden.

Next Steps

The company plans to raise additional capital in 2024.
The company plans to remediate material weaknesses in internal controls.
The company will continue to commercialize UltraMIST and PACE systems.
The company will file a registration statement with the SEC on or before December 17, 2024, for the resale of shares issued in the private placement.

Key Dates

Date	Description
2020-08-31	Reference to Senior Secured Promissory Notes Payable.
2022-02-01	Reference to Second Amendment to Note and Warrant Purchase and Security Agreement.
2022-02-28	Reference to Second Amendment to Note and Warrant Purchase and Security Agreement.
2022-08-31	Reference to Securities Purchase Agreement and Future Advance Convertible Promissory Notes.
2022-11-03	Reference to Securities Purchase Agreement and Future Advance Convertible Promissory Notes.
2023-01-01	Various references to financial activities.
2023-05-31	Reference to Securities Purchase Agreement and Future Advance Convertible Promissory Notes.
2023-07-01	Various references to financial activities.
2023-07-31	Reference to Asset-Backed Secured Promissory Notes.
2023-09-30	End of the reporting period for the financial statements.
2023-12-31	Various references to financial activities and end of the fiscal year.
2024-01-01	Various references to financial activities.
2024-01-21	Maturity date of Asset-Backed Secured Promissory Notes and conversion to Convertible Notes.
2024-01-31	Reference to Securities Purchase Agreement and Future Advance Convertible Promissory Notes.
2024-02-29	Reference to SEPAcquisitionCorpMember.
2024-03-31	Reference to License and Option Agreement.
2024-05-31	Reference to Securities Purchase Agreement and Future Advance Convertible Promissory Notes.
2024-06-01	Reference to CelularityMember.
2024-06-03	Various references to financial activities.
2024-06-25	Company terminated the Merger Agreement with SEPA.
2024-07-01	Various references to financial activities.
2024-09-30	End of the reporting period for the financial statements.
2024-10-16	Company entered into a securities purchase agreement for a private placement.
2024-10-17	Company entered into a Consent and Limited Waiver to Note and Warrant Purchase and Security Agreement.
2024-10-18	Reverse stock split and Note and Warrant Exchange completed.
2024-10-22	The HealthTronics Note was paid in full.

Keywords

SANUWAVE Health, revenue growth, financial results, UltraMIST, PACE, senior secured debt, going concern, reverse stock split, warrant liability, internal controls

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.